{"id":390750,"date":"2017-12-27T00:00:00","date_gmt":"2017-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0008-2017-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-05-02T23:38:05","modified_gmt":"2026-05-02T23:38:05","slug":"dlsfcg0008-2017-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0008-2017-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Osteoarthritic Pain | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>Osteoarthritic (<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>) pain represents the second-largest segment of the overall chronic pain market, affecting more than 70 million patients with\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0in the G7. The\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0pain market represents a lucrative opportunity for drug developers given the residual unmet need for more-effective and safe therapies, particularly agents that offer a distinct mechanism of action that more strongly correlates with the nature of this type of pain.\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0pain is predominately treated with cost-effective generic nonsteroidal anti-inflammatory drugs (<abbr data-original-title=\"nonsteroidal anti-inflammatory drug\" title=\"\">NSAID<\/abbr>s) and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics and new combinations of existing\u00a0<abbr data-original-title=\"nonsteroidal anti-inflammatory drug\" title=\"\">NSAID<\/abbr>s that attempt to mitigate side effects are also frequently prescribed. Emerging therapies, such as biological drugs from Regeneron\/Teva\/Mitsubishi Tanabe Pharma and Pfizer\/Eli Lilly that target nerve growth factor (<abbr data-original-title=\"nerve growth factor\" title=\"\">NGF<\/abbr>), together with the increasing number of patients diagnosed with\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0pain\u00a0due to lifestyle influences, will be key drivers of market growth through 2026.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How do interviewed experts perceive the\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0pain marketplace to be changing given the emphasis on the risk of abuse\/misuse with opioid analgesics?<\/li>\n<li>What effect will the recent launches of new analgesics such as Iroko\u2019s Vivlodex and Purdue\u2019s Hysingla\u00a0<abbr data-original-title=\"extended release\" title=\"\">ER<\/abbr>\u00a0continue to have on the treatment paradigm?<\/li>\n<li>What will be the impact of a new drug class, the emerging anti-<abbr data-original-title=\"nerve growth factor\" title=\"\">NGF<\/abbr>\u00a0biologic therapies, on the treatment landscape, given their reputed robust efficacy but considering also lingering concerns over safety seen in initial testing?<\/li>\n<li>What market share can developers of emerging therapies expect to obtain in the large patient population? What are the key drivers and constraints in the\u00a0<abbr data-original-title=\"osteoarthritis\" title=\"\">OA<\/abbr>\u00a0pain market?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390750","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoarthritic-pain","biopharma-therapy-areas-osteoarthritis","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390750\/revisions"}],"predecessor-version":[{"id":576755,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390750\/revisions\/576755"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}